Clinical Trial Update: Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update describes giving gene-marked EBV-specific T-cells to patients receiving a bone marrow transplant for relapsed EBV-positive Hodgk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Gene-marked EBV-specific T-cells

Snippet

Sponsor: Baylor College of Medicine | Conditions: Hodgkin Disease, Non-Hodgkins Lymphoma | Phase 1 | Status: TERMINATED